1132088-63-1
1132088-63-1
Chemical Structure
Valganciclovir-d8
- CAS No.: 1132088-63-1
- Formula:C14H14D8N6O5
- Molecular Weight:362.41
IUPAC Name: 5-(naphthalen-2-yl)-1H-pyrazole-3-carbohydrazide
InChIKey: WPVFJKSGQUFQAP-QBZXRSFMSA-N
SMILES: [2H]C([2H])([2H])C(C([2H])([2H])[2H])([2H])[C@@](N)([2H])C(OCC(CO)OCN1C2=C(C(N=C(N2)N)=O)N=C1)=O
Biological Activity: Valganciclovir-d8 is the deuterium labeled Valganciclovir [1]. Valganciclovir , the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Valganciclovir-d8 | Valganciclovir-d8 is the deuterium labeled Valganciclovir . Valganciclovir , the L-valyl ester of ganciclovir, is actually a proagent for ganciclovir. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valganciclovir hydrochloride (Standard) | ≥98% | Valganciclovir (hydrochloride) (Standard) is the analytical standard of Valganciclovir (hydrochloride). This product is intended for research and analytical applications. Valganciclovir hydrochloride is an orally active antiviral agent. Valganciclovir hydrochloride can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir hydrochloride can be used for the research of Cytomegalovirus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valganciclovir-d5 Hydrochloride | Valganciclovir-d5 (Hydrochloride) is deuterium labeled Valganciclovir (Hydrochloride). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Valganciclovir hydrochloride | 98.0% | Valganciclovir hydrochloride is an orally active antiviral agent. Valganciclovir hydrochloride can inhibit the growth of adenoviruses and have a protective effect on immunosuppressed hamsters. Valganciclovir hydrochloride can be used for the research of Cytomegalovirus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Sugawara M, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci. 2000 Jun;89(6):781-9. [Content Brief]
- [3]. Chawla JS, et al. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature. Transpl Infect Dis. 2012 Jun14(3):259-67. [Content Brief]
- [4]. O'Brien S, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15111(4):1816-9. [Content Brief]
